InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,460.80
(
0.24%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.50
(
0.45%
)
Bitcoin
65,151.58
(
1.80%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

stockbettor

Send PM Follow Ignore
Followers 3
Posts 278
Boards Moderated 0
Alias Born 03/08/2008

stockbettor

Re: pcrutch post# 133225

Saturday, 12/17/2011 4:56:14 PM

Saturday, December 17, 2011 4:56:14 PM

Post# of 251721
Her's a link to Synthon's PIII trial presumably needed for European approval:

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)
This study is currently recruiting participants.
Verified on December 2011 by Synthon BV


First Received on December 8, 2011. No Changes Posted
Sponsor: Synthon BV
Information provided by (Responsible Party): Synthon BV
ClinicalTrials.gov Identifier: NCT01489254

Purpose
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis

http://clinicaltrials.gov/ct2/show/NCT01489254
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up